The North America, Europe, and Asia Pacific legal cannabis market size is expected to reach USD 89.8 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 22.3% from 2023 to 2030. As more individuals become aware of the medical benefits of hemp, marijuana, and its derivatives, and as these products become more generally available, acceptance is expanding. Another key factor boosting market expansion is the increased acceptance of medicinal marijuana for the treatment of chronic diseases. Legalizing marijuana for adult use in many countries will assist in creating new job possibilities and add significantly to the economy. Tourism, real estate, finance, food, and transportation are just a few of the industries that will benefit from legalization. Manufacturers are facing challenges in setting up a functional and legalized channel for the development and trade of cannabis-derived products like cannabidiol due to the presence of strict laws.
The marijuana product segment led the market with a revenue share of over 74.5% in 2022. Marijuana for medical purposes is increasing in popularity as a result of recent legalizations in a number of nations. Patients with chronic diseases like Parkinson's disease, cancer, arthritis, Alzheimer's disease, and neurologic issues like depression, anxiety, and epilepsy are treated with marijuana. As a result, one of the primary reasons behind the expansion of this market is the widespread use of marijuana for the treatment of numerous chronic illnesses.
The CBD derivatives segment accounted for the largest revenue share in 2022 owing to the vast applications of these derivatives. It is extensively being used for medicinal purposes as well as for the cosmetic industry. In the APAC region, the cosmetic industry is a huge business and there has been a surge in the use of CBD derivatives in various skincare products. The others segment, being the fastest-growing category, is seeing an upward trend due to the increasing number of studies proving their prowess in the medical field.
The medical use segment emerged as the largest end-use segment in 2021. As medical cannabis is allowed in more countries than adult-use cannabis, the medical sector is likely to stay dominant during the forecast period. The increasing usage of cannabis and its derivatives in a variety of applications, including medicines, nutraceuticals, personal care and cosmetics, and edibles, is expected to increase the demand for these goods.
With a revenue share of over 84.3% in 2022, North America led the market. The availability of a large customer pool in the region and the early legalization of marijuana for medical and recreational use are major factors driving the market. Asia Pacific is predicted to be the fastest-growing market from 2022 to 2030 owing to the increased understanding of cannabis' medical and health benefits, which has prompted Asian countries to legalize cannabis and its derivatives.
During the pandemic, lockdowns and transit disruptions produced a disturbance in product supply, increasing the supply-demand disparity. As a result, the localized market and the worldwide market have been hampered. As customers gravitate away from traditional treatment approaches and move toward cannabis-based treatment, increased use of marijuana, largely for medicinal purposes, boosts the total market growth. Furthermore, the COVID-19 pandemic has significantly impacted the legal cannabis industry as a statewide lockdown has interrupted product production and imposed import/export restrictions, resulting in lower total revenue.
Request a free sample copy or view the report summary: North America, Europe & Asia Pacific Legal Cannabis Market Report
The market growth can be attributed to the greater use of hemp and marijuana products and increasing preference for medical marijuana. In addition, the upcoming legalization of marijuana for adult use is expected to boost growth over the predicted period
Due to the increased acceptance of marijuana for various medical illnesses, marijuana emerged as the leading source type in 2022
By end-use, the medical use segment held the largest revenue share in 2021. This is due to an increase in the product's use for chronic pain, mental illnesses such as anxiety, and sleep difficulties and increased knowledge among practitioners
Owing to the increasing consumption rate as a result of legalization, North America accounted for the largest revenue share in 2021
Grand View Research, Inc. has segmented the North America, Europe, and Asia Pacific legal cannabis market based on source type, derivatives, end-use, and region:
North America, Europe & Asia Pacific Legal Cannabis End-use Outlook (Revenue, USD Million, 2017 - 2030)
Marijuana
Flower
Oil & Tinctures
Hemp
Hemp CBD
Supplements
Industrial Hemp
North America, Europe & Asia Pacific Legal Cannabis Derivatives Outlook (Revenue, USD Million, 2017 - 2030)
CBD
THC
Others
North America, Europe & Asia Pacific Legal Cannabis End-use Outlook (Revenue, USD Million, 2017 - 2030)
Medical Use
Cancer
Chronic Pain
Depression and Anxiety
Arthritis
Diabetes
Glaucoma
Migraines
Epilepsy
Multiple Sclerosis
AIDS
Amyotrophic Lateral Sclerosis
Alzheimer’s
Post-Traumatic Stress Disorder (PTSD)
Parkinson's
Tourette’s
Others
Recreational Use
Industrial Use
Textile
Non-textile
North America, Europe & Asia Pacific Legal Cannabis Regional Outlook (Revenue, USD Million, 2017 - 2030)
North America
U.S.
Canada
Europe
Germany
Italy
Netherlands
Poland
Czech Republic
Switzerland
Asia Pacific
Australia
New Zealand
Thailand
Japan
South Korea
List of Key Players of North America, Europe & Asia Pacific Legal Cannabis Market
CANOPY GROWTH CORPORATION
Aurora Cannabis
Tilray
GW Pharmaceuticals, plc
Organigram Holdings Inc
Lexaria Bioscience Corp.
VIVO Cannabis Inc.
The Cronos Group
AusCann Group Holdings Ltd.
Cann Group Limited
Bod Australia
Zelira Therapeutics
Althea Group
THC Global Group Limited
MGC Pharma
ECOFIBRE
"The quality of research they have done for us has been excellent..."